Nyxoah (NASDAQ:NYXH) Stock Rating Raised to “Hold” at Wall Street Zen

Nyxoah (NASDAQ:NYXH) was upgraded by equities research analysts at Wall Street Zen from a “sell” rating to a “hold” rating in a research note issued on Saturday, Wall Street Zen reports.

Other research analysts have also recently issued research reports about the company. Raymond James Financial set a $3.00 price target on Nyxoah in a research note on Tuesday, October 27th. Oppenheimer set a $4.00 target price on shares of Nyxoah in a research report on Thursday, August 6th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Nyxoah in a report on Wednesday, August 19th. Robert W. Baird set a $2.31 target price on shares of Nyxoah in a report on Thursday, August 6th. Finally, Cantor Fitzgerald cut their price target on Nyxoah to $3.00 and set an “overweight” rating for the company in a research note on Tuesday, October 27th. Two equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, Nyxoah presently has an average rating of “Hold” and an average target price of $3.55.

Nyxoah Stock Performance

Shares of NASDAQ:NYXH opened at $0.85 on Friday. The company has a market cap of $32.78 million, a price-to-earnings ratio of -0.43 and a beta of 1.80. The company has a 50-day moving average price of $1.27 and a 200-day moving average price of $2.42. Nyxoah has a 12 month low of $0.80 and a 12 month high of $5.92. The company has a current ratio of 2.38, a quick ratio of 2.31 and a debt-to-equity ratio of 0.44.

Nyxoah (NASDAQ:NYXH) last announced its quarterly earnings data on Thursday, November 5th. The company reported ($0.20) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.24) by $0.04. The business had revenue of $10.39 million during the quarter, compared to the consensus estimate of $11.00 million. Nyxoah had a negative net margin of 443.16% and a negative return on equity of 178.90%. As a group, equities analysts anticipate that Nyxoah will post -1.46 EPS for the current year.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in NYXH. AIGH Capital Management LLC increased its stake in Nyxoah by 0.7% in the 3rd quarter. AIGH Capital Management LLC now owns 14,632,880 shares of the company’s stock worth $20,193,000 after purchasing an additional 98,000 shares during the period. Readystate Asset Management LP purchased a new position in shares of Nyxoah in the second quarter worth $351,000. IFP Advisors Inc increased its stake in shares of Nyxoah by 35.6% during the second quarter. IFP Advisors Inc now owns 118,426 shares of the company’s stock worth $200,000 after purchasing an additional 31,061 shares in the last quarter. Finally, Integrated Wealth Concepts LLC acquired a new stake in shares of Nyxoah in the second quarter valued at $169,000.

Nyxoah Company Profile

Nyxoah SA is a medical technology company focused on developing and commercializing solutions for obstructive sleep apnea (OSA), a common sleep-related breathing disorder. The company is headquartered in Mont-Saint-Guibert, Belgium, and its shares trade on the Nasdaq under the symbol NYXH.

Nyxoah’s principal product is the Genio system, an implantable, rechargeable device designed to treat OSA through hypoglossal nerve stimulation. The system is intended to help maintain an open airway during sleep by stimulating the nerves that control the tongue and related upper-airway muscles.